FHLC - ETF AI Analysis
Top Page
Fidelity MSCI Health Care Index ETF (FHLC)
Rating:72Outperform
Price Target:―
Positive Factors
Low Expense Ratio
The fund charges relatively low fees, which helps investors keep more of their returns over time.
Broad Health Care Exposure
The ETF holds a wide range of health care companies across pharmaceuticals, equipment, and services, reducing reliance on any single business.
Large, Established Top Holdings
Many of the biggest positions are well-known, mature health care companies with generally steady performance, which can add stability to the fund.
Negative Factors
Sector Concentration Risk
Almost all assets are in the health care sector, so the fund could be hit hard if health care stocks fall out of favor.
Heavy Reliance on a Few Stocks
A small number of companies, especially the largest holding, make up a significant share of the portfolio, increasing the impact if those stocks struggle.
Recent Weak Overall Performance
The ETF’s returns over the year to date and recent three-month period have been weak, suggesting the health care sector has faced headwinds lately.
FHLC vs. SPDR S&P 500 ETF (SPY)
AUM2.85B
RegionNorth America
Expense Ratio0.08%
Beta0.55
IssuerFidelity
Inception DateOct 21, 2013
Dividend Yield1.45%
Asset ClassEquity
Index TrackedMSCI US IMI 25/50 Health Care
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume215,724
30 Day Avg. Volume173,501
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
87.62Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering331
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FHLC Summary
The Fidelity MSCI Health Care Index ETF (FHLC) is a fund that follows the MSCI US IMI 25/50 Health Care Index, giving you broad exposure to U.S. health care companies. It holds well-known names like Eli Lilly and Johnson & Johnson, along with drug makers, medical device companies, and health care service providers. Someone might invest in FHLC to tap into the long-term growth and stability of the health care sector while spreading risk across many companies. A key risk is that it is heavily concentrated in health care, so it can rise or fall with that sector’s fortunes.
How much will it cost me?The Fidelity MSCI Health Care Index ETF (FHLC) has an expense ratio of 0.084%, meaning you’ll pay $0.84 per year for every $1,000 invested. This is lower than average because it is passively managed, tracking an index rather than relying on active management strategies.
What would affect this ETF?The FHLC ETF, focused on the U.S. health care sector, could benefit from ongoing innovation in biotechnology and pharmaceuticals, as well as increasing demand for health care services driven by aging populations and advancements in medical technology. However, it may face challenges from regulatory changes, drug pricing pressures, or economic downturns that could impact health care spending. Its reliance on top holdings like Eli Lilly and Johnson & Johnson means company-specific events could also significantly influence performance.
FHLC Top 10 Holdings
FHLC is a pure U.S. health care play, and its story right now is one of a few heavyweights steering the ship. UnitedHealth has been rising lately and helps keep the fund’s pulse strong, while steady names like Johnson & Johnson and Merck provide a calmer backbone. On the flip side, Eli Lilly’s recent slide after an earlier run-up, along with weakness in Thermo Fisher, Abbott, and Intuitive Surgical, has been dragging on returns. With so much riding on a handful of big drug and equipment makers, the fund is both focused and a bit top-heavy.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 11.60% | $327.86M | $835.18B | -1.03% | 72 Outperform | |
| Johnson & Johnson | 8.95% | $252.98M | $547.64B | 45.05% | 78 Outperform | |
| AbbVie | 5.73% | $162.10M | $351.47B | 2.62% | 66 Neutral | |
| UnitedHealth | 5.25% | $148.39M | $322.15B | -15.55% | 72 Outperform | |
| Merck & Company | 4.53% | $128.19M | $276.38B | 32.50% | 80 Outperform | |
| Amgen | 3.03% | $85.63M | $185.95B | 20.17% | 77 Outperform | |
| Thermo Fisher | 2.88% | $81.46M | $174.55B | 11.08% | 72 Outperform | |
| Intuitive Surgical | 2.79% | $78.90M | $170.78B | -8.37% | 78 Outperform | |
| Gilead Sciences | 2.64% | $74.67M | $161.86B | 20.13% | 78 Outperform | |
| Abbott Laboratories | 2.59% | $73.14M | $158.72B | -28.36% | 73 Outperform |
FHLC Technical Analysis
Neutral
―
Price Trends
71.54
Negative
72.98
Negative
70.08
Positive
Market Momentum
-0.42
Positive
46.38
Neutral
38.11
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FHLC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 70.68, equal to the 50-day MA of 71.54, and equal to the 200-day MA of 70.08, indicating a neutral trend. The MACD of -0.42 indicates Positive momentum. The RSI at 46.38 is Neutral, neither overbought nor oversold. The STOCH value of 38.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FHLC.
FHLC Peer Comparison
Comparison Results
Performance Comparison
FHLC
Fidelity MSCI Health Care Index ETF
70.11
5.98
9.32%
VHT
Vanguard Health Care ETF
―
―
―
XBI
SPDR S&P BIOTECH ETF
―
―
―
IBB
iShares Biotechnology ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents